Lipid distributions in the Global Diagnostics Network across five continents.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
01 Jul 2023
Historique:
received: 19 11 2022
revised: 07 04 2023
accepted: 24 05 2023
medline: 3 7 2023
pubmed: 1 7 2023
entrez: 1 7 2023
Statut: ppublish

Résumé

Lipids are central in the development of cardiovascular disease, and the present study aimed to characterize variation in lipid profiles across different countries to improve understanding of cardiovascular risk and opportunities for risk-reducing interventions. This first collaborative report of the Global Diagnostics Network (GDN) evaluated lipid distributions from nine laboratory organizations providing clinical laboratory testing in 17 countries on five continents. This cross-sectional study assessed aggregated lipid results from patients aged 20-89 years, tested at GDN laboratories, from 2018 through 2020. In addition to mean levels, the World Health Organization total cholesterol risk target (<5.00 mmol/L, <193 mg/dL) and proportions in guideline-based low-density lipoprotein cholesterol (LDL-C) categories were assessed. This study of 461 888 753 lipid results found wide variation by country/region, sex, and age. In most countries, total cholesterol and LDL-C peaked at 50-59 years in females and 40-49 years in males. Sex- and age-group adjusted mean total cholesterol levels ranged from 4.58 mmol/L (177.1 mg/dL) in the Republic of Korea to 5.40 mmol/L (208.8 mg/dL) in Austria. Mean total cholesterol levels exceeded the World Health Organization target in Japan, Australia, North Macedonia, Switzerland, Germany, Slovakia, and Austria. Considering LDL-C categories, North Macedonia had the highest proportions of LDL-C results >4.91 mmol/L (>190 mg/dL) for both females (9.9%) and males (8.7%). LDL-C levels <1.55 mmol/L (<60 mg/dL) were most common among females in Canada (10.7%) and males in the UK (17.3%). With nearly a half billion lipid results, this study sheds light on the worldwide variability in lipid levels, which may reflect inter-country differences in genetics, lipid testing, lifestyle habits, and pharmacologic treatment. Despite variability, elevated atherogenic lipid levels are a common global problem, and these results can help inform national policies and health system approaches to mitigate lipid-mediated risk of cardiovascular disease.

Identifiants

pubmed: 37392135
pii: 7216561
doi: 10.1093/eurheartj/ehad371
pmc: PMC10314323
doi:

Substances chimiques

Cholesterol, LDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2305-2318

Subventions

Organisme : NIH HHS
ID : R01AG071032, P01 HL108800
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Circulation. 2023 Feb 21;147(8):e93-e621
pubmed: 36695182
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Korean J Intern Med. 2019 Jul;34(4):723-771
pubmed: 31272142
Lancet. 2001 Mar 31;357(9261):995-1001
pubmed: 11293642
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Cardiovasc Diagn Ther. 2017 Dec;7(6):633-639
pubmed: 29302468
Glob Heart. 2022 Oct 14;17(1):75
pubmed: 36382159
Eur Heart J. 2003 Sep;24(17):1601-10
pubmed: 12964575
Curr Cardiol Rep. 2021 Aug 19;23(10):136
pubmed: 34410520
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Eur Heart J. 2022 Feb 22;43(8):830-833
pubmed: 34636884
Circulation. 1992 Sep;86(3):858-69
pubmed: 1516198
JAMA. 2005 Oct 12;294(14):1773-81
pubmed: 16219880
J Am Coll Cardiol. 2021 Nov 2;78(18):1817-1830
pubmed: 34711341
Eur Heart J. 2021 Jul 1;42(25):2455-2467
pubmed: 34120185
Can J Cardiol. 2022 Aug;38(8):1180-1188
pubmed: 35378262
Clin Cardiol. 2013 Nov;36(11):641-8
pubmed: 24122913
J Am Heart Assoc. 2014 Apr 22;3(2):e000851
pubmed: 24755154
JAMA. 2013 Nov 20;310(19):2061-8
pubmed: 24240933
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418
pubmed: 36031461
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Aging Dis. 2020 Oct 1;11(5):1046-1057
pubmed: 33014521

Auteurs

Seth S Martin (SS)

Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Carnegie 591, Baltimore, MD 21287, USA.

Justin K Niles (JK)

Quest Diagnostics, Secaucus, NJ, USA.

Harvey W Kaufman (HW)

Quest Diagnostics, Secaucus, NJ, USA.

Zuhier Awan (Z)

King Abdulaziz University, Jeddah, Saudi Arabia.
Al Borg Diagnostics, Jeddah, Saudi Arabia.

Ola Elgaddar (O)

Al Borg Diagnostics, Jeddah, Saudi Arabia.
Medical Research Institute, Alexandria University, Alexandria, Egypt.

Rihwa Choi (R)

GC Labs, Yongin, Republic of Korea.
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Sunhyun Ahn (S)

GC Labs, Yongin, Republic of Korea.

Rajan Verma (R)

Strand Life Sciences, Bengaluru, India.

Mahesh Nagarajan (M)

Strand Life Sciences, Bengaluru, India.

Andrew Don-Wauchope (A)

McMaster University, Hamilton, Ontario, Canada.
LifeLabs Inc., Toronto, Ontario, Canada.

Maria Helane Costa Gurgel Castelo (MHC)

Dasa, Fortaleza/Ceará, Brazil.

Caio Kenji Hirose (CK)

Dasa, Fortaleza/Ceará, Brazil.

David James (D)

SYNLAB, Southwest Pathology Service, London, UK.

Derek Truman (D)

SYNLAB, Southwest Pathology Service, London, UK.

Maja Todorovska (M)

SYNLAB, North Macedonia, Macedonia.

Ana Momirovska (A)

SYNLAB, North Macedonia, Macedonia.

Monika Rákociová (M)

SYNLAB, Slovakia.

Janserey Batu (J)

SYNLAB, Ankara, Turkey.

Nehmat El Banna (N)

SYNLAB, Freiburg Medical Laboratory, UAE.

Hema Kapoor (H)

Quest Diagnostics, Secaucus, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH